Ciftci Seyfettin, Ozkurkcugil Cuneyd, Yilmaz Hasan, Ustuner Murat, Yavuz Ufuk, Yuksekkaya Mustafa, Cekmen Mustafa Baki
Department of Urology, Sivas Numune Hospital, Sivas, Turkey.
Department of Urology, School Medicine, University of Kocaeli, Kocaeli, Turkey.
Int Urogynecol J. 2016 Feb;27(2):275-80. doi: 10.1007/s00192-015-2825-3. Epub 2015 Aug 27.
We evaluated changes in urinary nerve growth factor (NGF) and NGF/creatinine (NGF/Cr) levels after increasing the dosage of solifenacin in overactive bladder patients.
The study groups included 59 overactive bladder (OAB) patients and 20 healthy subjects as controls. We measured NGF at baseline for the patients and controls, and used the Overactive Bladder Awareness Tool (OAB-V8) to evaluate urinary symptoms. All patients received a treatment of solifenacin 5 mg for 6 weeks. The responders to treatment served as group 1 and nonresponders received solifenacin 10 mg for an additional 6 weeks. Responders and nonresponders to the 10-mg treatment were defined as groups 2 and 3 respectively. NGF was measured after each treatment using the ELISA method and normalized by the urinary creatinine levels (NGF/Cr).
There were 21, 22 and 16 patients in groups 1, 2, and 3 respectively. At baseline, the NGF and NGF/Cr levels were higher in groups 1, 2, and 3 compared with the controls. After the solifenacin 5 mg treatment, the NGF and NGF/Cr levels of group 1 individuals decreased to those of the control level. After increasing the dosage of solifenacin to 10 mg in group 2, the NGF and NGF/Cr levels decreased to normal levels. In group 3 (patients who did not responded to any treatment), these levels remained unchanged.
Our results suggest that urinary NGF could be a potential biomarker for monitoring the treatment of symptoms in OAB patients who are treated with solifenacin.
我们评估了膀胱过度活动症患者增加索利那新剂量后尿神经生长因子（NGF）及NGF/肌酐（NGF/Cr）水平的变化。
研究组包括59例膀胱过度活动症（OAB）患者和20例健康受试者作为对照。我们在基线时测量了患者和对照的NGF，并使用膀胱过度活动症认知工具（OAB-V8）评估尿路症状。所有患者接受5 mg索利那新治疗6周。治疗有反应者作为第1组，无反应者再接受10 mg索利那新治疗6周。10 mg治疗的有反应者和无反应者分别定义为第2组和第3组。每次治疗后使用ELISA法测量NGF，并通过尿肌酐水平进行标准化（NGF/Cr）。
第1组、第2组和第3组分别有21例、22例和16例患者。基线时，第1组、第2组和第3组的NGF和NGF/Cr水平高于对照组。5 mg索利那新治疗后，第1组个体的NGF和NGF/Cr水平降至对照水平。第2组将索利那新剂量增加至10 mg后，NGF和NGF/Cr水平降至正常水平。在第3组（对任何治疗均无反应的患者）中，这些水平保持不变。
我们的结果表明，尿NGF可能是监测接受索利那新治疗的OAB患者症状治疗的潜在生物标志物。
